---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028363"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:43:50.859535+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics appoints Dr. Srini Tenjarla as SVP of CMC and Formulation

## Summary
- Tenjarla joins from Takeda, where he was VP and Head of Drug Product Development.
- At Takeda he oversaw phase-appropriate development from Phase 1 through validation.
- Previously held leadership roles at Shire, including VP of Pharmaceutical Sciences.
- He holds a Ph.D. in Pharmaceutical Sciences from the University of Houston.
- Appointment effective July 15, 2024; will oversee CMC activities across pipeline.

## SEC filing metadata
- accession: 0001493152-24-028363
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/0001493152-24-028363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028363
- JSON: https://secwatch.observer/filing/0001493152-24-028363.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028363.txt

## Key facts
- Executive change
  Srini Tenjarla was appointed as Senior Vice President, CMC & Formulation at Serina Therapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President, CMC & Formulation
  source text: On July 18, 2024, Serina Therapeutics, Inc. (the “ Company ”) announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/0001493152-24-028363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.